Skip to search formSkip to main contentSkip to account menu

Quizartinib

Known as: (2E)-N-(4-(3-Chloro-4-Fluoroanilino)-7-(((3S)-Oxolan-3-Yl)Oxy)Quinoxazolin-6-yl)-4-(Dimethylamino)but-2-Enamide, AC220 compound, N-(5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-morpholin-4-yl-ethoxy)imidazo [2,1-b] [1,3] benzothiazol 2-yl]phenyl}urea 
An orally available small molecule with potential antineoplastic activity. Quizartinib selectively inhibits class III receptor tyrosine kinases… 
National Institutes of Health

Related topics

Related topics

6 relations
AC220NCIt Antineoplastic Agent TerminologyQuizartinib DihydrochlorideReceptor Tyrosine Kinase Inhibition

Broader (2)

BenzothiazolesPhenylurea Compounds

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Laboratory and Clinical Investigations to Identify the Optimal Dosing Strategy for Quizartinib (AC220) Monotherapy in FLT3-Itd-Positive (+) Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML)
Internal tandem duplications (ITD) are the most commonly observed FLT3 mutations in AML and are associated with decreased… 
2015
2015
Quizartinib Significantly Improves Overall Survival in FLT3-ITD Positive AML Patients Relapsed after Stem Cell Transplantation or after Failure of Salvage Chemotherapy: A Comparison with Historical…
Introduction: The prognosis of patients with a FLT3-ITD mutation in acute myeloid leukemia (AML) is worse than FLT3 wild type… 
2014
2014
Use of sorafenib for post-transplant relapse in FLT3/ITD-positive acute myelogenous leukemia: maturation induction and cytotoxic effect
Internal tandem duplication (ITD) mutation of the FLT3 receptor tyrosine kinase ( FLT3/ITD ) is one of the most common gene… 
Review
2013
Review
2013
The role of quizartinib in the treatment of acute myeloid leukemia
Introduction: Approximately one-third of the patients with acute myeloid leukemia (AML) harbor internal tandem duplication (ITD… 
2013
2013
New mesomorphic benzothiazol derivatives: Synthesis and characterization
2013
2013
Effect of quizartinib (AC220) on response rates and long-term survival in elderly patients with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia.
7021 Background: Advanced age and FMS-like tyrosine kinase 3 internal tandem duplications (FLT3-ITD) in acute myeloid leukemia… 
2013
2013
Response rate and bridging to hematopoietic stem cell transplantation (HSCT) with quizartinib (AC220) in patients with FLT3-ITD positive or negative relapsed/refractory AML after second-line…
7012 Background: FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in acute myeloid leukemia (AML) is associated… 
2013
2013
Efficacy and safety of quizartinib (AC220) in patients age ≥ 70 years with FLT3-ITD positive or negative relapsed/refractory acute myeloid leukemia (AML).
7023 Background: Advanced age and FMS-like tyrosine kinase 3 internal tandem duplication (FLT3-ITD) in AML are each associated… 
2012
2012
A Phase I Study Of AC220 (Quizartinib) In Combination With Cytarabine and Etoposide In Relapsed/Refractory Childhood ALL and AML: A Therapeutic Advances In Childhood Leukemia & Lymphoma (TACL) Study
Background AC220 is a novel class III receptor tyrosine kinase (RTK) inhibitor that is potent and highly selective for mutant and… 
Highly Cited
1989
Highly Cited
1989
The popliteal lymph node assay in mice to screen for the immune disregulating potential of chemicals--a preliminary study.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)